Literature DB >> 9672236

Beta-chemokines and protection from HIV type 1 disease.

A Garzino-Demo1, A L DeVico, F Cocchi, R C Gallo.   

Abstract

A small revolution has occurred in the field of AIDS research. A number of chemokines, most of which belong to the CC or beta family, were found by us and others to inhibit HIV infection potently and specifically. The mechanism of such inhibition was shown to be at the level of receptor binding, as these chemokines are binding to receptors that mediate HIV infection. Therefore, chemokines effectively block entry of HIV. Although chemokines have a natural function as chemoattractants, it is intriguing to think that in crossing their path with the virus, they constitute the first example of a naturally occurring soluble molecule, other than antibodies, that can specifically prevent infection. Thus, chemokines could play a role in protective immunity against HIV infection together with other classic correlates, such as neutralizing antibodies and cytotoxic T cells, and some clinical studies suggest that this is indeed the case. Here we review and analyze some of the basic and clinical science that led to the elucidation of the role of chemokines and their receptor in protection from HIV infection.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9672236

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  11 in total

1.  Spontaneous and antigen-induced production of HIV-inhibitory beta-chemokines are associated with AIDS-free status.

Authors:  A Garzino-Demo; R B Moss; J B Margolick; F Cleghorn; A Sill; W A Blattner; F Cocchi; D J Carlo; A L DeVico; R C Gallo
Journal:  Proc Natl Acad Sci U S A       Date:  1999-10-12       Impact factor: 11.205

Review 2.  Type I Interferons in NeuroHIV.

Authors:  Victoria E Thaney; Marcus Kaul
Journal:  Viral Immunol       Date:  2018-09-27       Impact factor: 2.257

3.  Cocaine differentially modulates chemokine production by mononuclear cells from normal donors and human immunodeficiency virus type 1-infected patients.

Authors:  M P Nair; K C Chadha; R G Hewitt; S Mahajan; A Sweet; S A Schwartz
Journal:  Clin Diagn Lab Immunol       Date:  2000-01

4.  Slowly declining levels of viral RNA and DNA in DNA/recombinant modified vaccinia virus Ankara-vaccinated macaques with controlled simian-human immunodeficiency virus SHIV-89.6P challenges.

Authors:  Yuyang Tang; Francois Villinger; Silvija I Staprans; Rama Rao Amara; James M Smith; James G Herndon; Harriet L Robinson
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

Review 5.  DNA vaccines against human immunodeficiency virus type 1 in the past decade.

Authors:  Malavika Giri; Kenneth E Ugen; David B Weiner
Journal:  Clin Microbiol Rev       Date:  2004-04       Impact factor: 26.132

6.  Enhancement of human immunodeficiency virus type 1 infection by the CC-chemokine RANTES is independent of the mechanism of virus-cell fusion.

Authors:  C J Gordon; M A Muesing; A E Proudfoot; C A Power; J P Moore; A Trkola
Journal:  J Virol       Date:  1999-01       Impact factor: 5.103

Review 7.  Evolution of cell recognition by viruses: a source of biological novelty with medical implications.

Authors:  Eric Baranowski; Carmen M Ruiz-Jarabo; Nonia Pariente; Nuria Verdaguer; Esteban Domingo
Journal:  Adv Virus Res       Date:  2003       Impact factor: 9.937

8.  Longitudinal comparison of chemokines in breastmilk early postpartum among HIV-1-infected and uninfected Kenyan women.

Authors:  Rose Bosire; Brandon L Guthrie; Barbara Lohman-Payne; Jennifer Mabuka; Maxwell Majiwa; Grace Wariua; Dorothy Mbori-Ngacha; Barbra Richardson; Grace John-Stewart; Carey Farquhar
Journal:  Breastfeed Med       Date:  2007-09       Impact factor: 1.817

Review 9.  HIV-1 associated dementia: update on pathological mechanisms and therapeutic approaches.

Authors:  Marcus Kaul
Journal:  Curr Opin Neurol       Date:  2009-06       Impact factor: 5.710

10.  Interactive Effects of Morphine on HIV Infection: Role in HIV-Associated Neurocognitive Disorder.

Authors:  Pichili Vijaya Bhaskar Reddy; Sudheesh Pilakka-Kanthikeel; Shailendra K Saxena; Zainulabedin Saiyed; Madhavan P N Nair
Journal:  AIDS Res Treat       Date:  2012-05-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.